摘要
他汀类药物(statins)是动脉粥样硬化性心血管疾病(ASCVD)一级预防和二级预防的重要药物之一,但长期使用他汀类药物与新发糖尿病(NODM)发生风险增加相关,这一现象引起人们广泛关注。匹伐他汀作为第三代新型他汀类药物,安全性和耐受性良好,被誉为"超级他汀"。目前,匹伐他汀与NODM发生风险的结论不一,有研究表明其对糖代谢无不良影响,甚至可以改善糖尿病患者的胰岛素抵抗。但也有学者认为增加NODM风险是他汀药物的类效应,匹伐他汀也不例外。现对近年来有关匹伐他汀对糖代谢影响的研究进展予以综述。
Statins is an effective drug with proven benefits in the primary and secondary prevention of atherosclerotic cardiovascular disease(ASCVD).However,several clinical researches indicate that the long-term use of statins may increase the risk of new-onset diabetes mellitus(NODM).Pitavastatin,as a newest form of statins,is called'super statin'because of its better safety and tolerability.The correlation between pitavastatin and NODM risk is inconsistent.Some research indicated that pitavastatin had no negative effect on glucose metabolism,and might even improve insulin resistance.While,some other researchers consider that increased NODM risk is a kind of effect for all statins,including pitavastatin.This review summarizes the research progress on the effect of pitavastatin and glucose metabolism.
作者
闫芮
马鑫
吕冰慧
王继伟
余金明
YAN Rui;MA Xin;LV Binghui;WANG Jiwei;YU Jinming(Institute of Clinical Epidemiology,School of Public Health,Fudan University,Shanghai 200032,China;JiangsuWanbang Medicine Marketing Co.,Xuzhou,Jiangsu 221004,China)
出处
《中国动脉硬化杂志》
CAS
2019年第3期185-189,共5页
Chinese Journal of Arteriosclerosis
基金
国家重点研发计划(2017YFC1307600)
国家社会科学基金(13CSH76)
关键词
匹伐他汀
糖代谢
新发糖尿病
pitavastatin
glucose metabolism
new-onset diabetes mellitus
